FDA approves Lilly Alimta (injection pemele) with a new indication
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the U.SPharmaceuticalsannounced that the U.SFood andDrug(
FDA( ) has approved alimta (injection-based pemephore) combined carboplatin and Mercado-1 immunotherapy Keytruda (Pembrolizumab) for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NCLSC)in May 2017, Mercadon received accelerated approval for keytruda and Alimta combination drugsthis is the first and only FDA-approved combination of chemotherapy-immune therapy for metastatic non-scaly NSCLCthe approval is based on data on queue G1 in the KEYNOTE-021 study conducted by MercadoCohorg G1 enrolled in 123 patients with pre-treated (initially treated) localized advanced or metastatic non-scaly NSCLC patients without EGFR or ALK genomic tumor distortion, regardless of PD-L1 expressiondata show a statistically significant improvement in the objective mitigation rate of the Keytruda-Alimta-Caplatinum triple-combination (n-60) (ORR:55% vs29) compared to the Alimta-Caplatinum treatment group (n-63) %, all are partially alleviated; estimated variance: 26%, triple group 95% CI: 42-68, Alimta and Caplatinum group 95% CI: 0.31-0.91, p-0.0205)median PFS, the triple group is 13.0 months (range: 8.3 months-NE) and the Alimta-Caplatinum group is 8.9 months (range: 4.4-10.3 months)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
